Share “News Summary: Charges help cut Merck Q4...”

News Summary: Charges help cut Merck Q4 profit

Published on NewsOK Modified: February 1, 2013 at 4:46 pm •  Published: February 1, 2013
Advertisement

PROFIT DROP: Lower sales due to generic competition and one-time charges cut Merck & Co.'s fourth-quarter profit by 7 percent, to $1.4 billion, or 46 cents per share. Sales were down 5 percent, at $11.74 billion.

UNEXPECTED DELAY: Merck said it's reviewing safety and efficacy data from a crucial late-stage patient test of its experimental osteoporosis drug. It will hold off from applying for approval of the drug, odanacatib, until 2014. It had originally planned file in the first half of this year.

FINANCIAL FORECAST: Merck expects 2013 earnings per share of $3.60 to $3.70, excluding charges, and revenue around $47 billion.


AROUND THE WEB

  1. 1
    Neurologist and Writer Oliver Sacks Dies at 82
  2. 2
    What "Games Of Thrones" Characters Look Like In The Books
  3. 3
    Three Injured In Head-On Collision In Norman
  4. 4
    Chicago’s Polish Triangle
  5. 5
    How to fly cross country without using airports
+ show more

FEATURED JOBS



× Trending business Article